

S 777

End Taxpayer Funding of Gender Experimentation Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Mar 16, 2021

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Mar 16, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/777>

Sponsor

Name: Sen. Marshall, Roger [R-KS]

Party: Republican • **State:** KS • **Chamber:** Senate

Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Blackburn, Marsha [R-TN]	R · TN		Mar 16, 2021
Sen. Braun, Mike [R-IN]	R · IN		Mar 16, 2021
Sen. Cotton, Tom [R-AR]	R · AR		Mar 16, 2021
Sen. Hyde-Smith, Cindy [R-MS]	R · MS		Mar 16, 2021
Sen. Lee, Mike [R-UT]	R · UT		Mar 16, 2021
Sen. Daines, Steve [R-MT]	R · MT		Feb 14, 2022
Sen. Wicker, Roger F. [R-MS]	R · MS		Apr 26, 2022

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Mar 16, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 8731	Related bill	Nov 1, 2022: Referred to the Subcommittee on Immigration and Citizenship.
117 HR 1927	Identical bill	May 18, 2021: Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.

End Taxpayer Funding of Gender Experimentation Act of 2021

This bill modifies provisions relating to federal funding for, and health insurance coverage of, gender reassignment medical interventions, which include surgical remedies and hormone therapy arising from a conflict between an individual's gender identity and the sex the individual has or was identified as having at birth. Specifically, the bill prohibits the use of federal funds for gender reassignment medical interventions or for health coverage that includes such interventions. Additionally, such interventions may not be provided in a federal health care facility or by a federal employee. Under current law, coverage of these interventions through Medicare and Medicaid is generally determined at the state level.

The bill's restrictions regarding the use of federal funds do not apply to treatment of individuals with medically verifiable disorders of sex development, such as individuals born with atypical development of chromosomal, gonadal, or anatomical sex.

The bill also prohibits qualified health plans from including coverage for gender reassignment medical interventions. Further, plans that include coverage for such interventions are not eligible for federal subsidies.

Actions Timeline

- **Mar 16, 2021:** Introduced in Senate
- **Mar 16, 2021:** Read twice and referred to the Committee on Finance.